Takeda
Takeda to buy LigoCyte for $60 million
October 8, 2012Sales and Marketing LigoCyte, Takeda, norovirus
Takeda Pharmaceutical Company is to pay $60 million upfront to buy private US biopharma firm LigoCyte Pharmaceuticals in the next …
Takeda opens Russian manufacturing facility
September 11, 2012Manufacturing and Production Actovegin, Nycomed, Russia, Takeda
Takeda Pharmaceutical has officially opened its new manufacturing facility in Yaroslavl, Russia, and expects it to be operating at full …
Generic Actos gains FDA approval
August 20, 2012Sales and Marketing Actos, Mylan, Ranbaxy, Takeda, diabetes, generic
Takeda’s big-selling diabetes pill Actos will have its US sales decimated after the FDA approves three copycat versions of the …
Speedy approval for Onyx’ multiple myeloma drug
July 24, 2012Research and Development, Sales and Marketing FDA, Janssen, Kyprolis, Onyx, Takeda, Velcade
Onyx’ Kyprolis has gained an accelerated approval by the FDA to treat patients with late-stage multiple myeloma. Kyprolis (carfilzomib), a …
Senior appointments for Takeda’s Europe and Canada team
July 18, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Takeda
Takeda Pharmaceuticals has appointed David Milton as head of Marketing & Product Portfolio Strategy, and Dr Nizamul Islam as head …
Takeda appoints new head of Corporate Communications, Europe and Canada
July 12, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda, communications
Takeda Pharmaceuticals has appointed Rob Gallo as head of Corporate Communications, Europe and Canada. Since 2010 Gallo has been the …
EMA publishes updated diabetes guidelines
July 2, 2012Research and Development, Sales and Marketing Avandia, EMA, GSK, R&D, Takeda
The European Medicines Agency has published new guidance on what it wants to see from firms submitting new diabetes treatments. …
Takeda makes changes to organisation
June 22, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Takeda
Takeda has announced the change of senior leadership and the establishment of a new organisation.Effective from July Masahiro Fujimaki becomes …
AstraZeneca buys Ardea Biosciences
June 22, 2012Research and Development, Sales and Marketing Abbott, Ardea Biosciences, AstraZeneca, Bayer, Humira, Takeda
AstraZeneca has completed its acquisition of US firm Ardea Biosciences in a $1.26 billion deal that it hopes will shore …
Takeda to buy gout specialist URL Pharma for $800m
April 16, 2012Research and Development, Sales and Marketing R&D, Takeda, acquisition, gout
Takeda is set to purchase URL Pharmaceuticals for $800 million, helping offset the loss of its blockbuster ulcer drug Prevacid. …
Approval for Affymax and Takeda’s anaemia treatment
March 29, 2012Sales and Marketing Affymax, Amgen, ESA, Epogen, Takeda, omontys
The first rival treatment to Amgen’s portfolio of anaemia drugs has been approved in the US.Omontys (peginesatide) has been developed …
Takeda to cut 2,800 jobs
January 19, 2012Business Services, Research and Development, Sales and Marketing Nycomed, Takeda, job cuts
Takeda has announced plans to significantly reduce its global headcount over the next four years following its merger with Nycomed. …
Pharma unprepared for annus horribilis
January 12, 2012Research and Development, Sales and Marketing AZ, Pfizer, Takeda, patents, pharma
A new survey shows pharma is not prepared to deal with the tough year ahead as many blockbuster drugs begin …
Dr Rajeev Venkayya to head Takeda’s new vaccine business
December 9, 2011Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Takeda
Takeda will establish a new vaccine business division in January next year and will appoint Dr Rajeev Venkayya as its …
Takeda completes Nycomed acquisition, installs new chief executive
October 3, 2011Sales and Marketing Nycomed, Takeda
Takeda Pharmaceutical Company has completed its acquisition of Nycomed and named Frank Morich as chief executive of the Zurich-based firm. …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
